Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving how doctors communicate with patients who have a type of cancer called large B-cell lymphoma, specifically a subtype known as diffuse large B-cell lymphoma (DLBCL). The study is testing a new training program called Hematolo-GIST, which aims to help oncologists have better conversations with their patients about their diagnosis and future care options.

To participate in this study, patients need to be at least 18 years old, be currently treated by a participating hematologic oncologist for DLBCL, and self-identify as Black and/or White. Additionally, they should have had a recent relapse or worsening of their lymphoma after initial treatments. Participants will be asked to complete certain study procedures, and they should be fluent in English to ensure they understand the discussions. This study is currently recruiting participants, and it presents an opportunity for patients to contribute to improving communication in cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hematologists
• • Currently a hemotologic oncologist providing care to patients with DLBCL
• • Patients
• • Per medical record, is being treated by a hematologic oncologist participating in this study
• • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
• • Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or autologous stem cell transplant (ASCT)
• • Self-identify as Black and/or White
• • Per medical record, 18 years of age or older
• * Per self-report, fluent in English\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
• • 1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
• • 2. What is your preferred language for healthcare? (must respond English)
• Exclusion Criteria:
• • Hematologists
• • Per self-report, planning to leave the cancer center in the next 12 months
• • Patients
• • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
• • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
• • Per medical record or self-report, receiving hospice care at the time of enrollment